bovnews3 小时
Johnson & Johnson (JNJ) Stock: A Deeper Look at Its True Potential
On Friday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $155.47 which represents a decrease of $-1.26 or -0.80% from the prior close of $156.73. The stock opened at $157 and touched ...
Business Insider16 小时
Bullish Outlook on Protagonist Therapeutics Amid Promising JNJ-2113 Phase 3 Trial Potential
Julian Harrison gave his rating based on several factors surrounding Protagonist Therapeutics’ promising drug candidate, JNJ-2113. The upcoming Phase 3 trial data for JNJ-2113 in psoriasis is pivotal, ...
Why Johnson & Johnson (JNJ)’s Legal Issues Could Wrap Up Quickly
The first time Johnson & Johnson faced a lawsuit due to its talc-based baby powder causing cancer was way back in 1999. Since ...
阿思達克財經網5 天
强生(JNJ.US)单抗疗法达到3期临床主要终点 显著延缓高风险SMM进展
摘要指出，Darzalex单药治疗耐受性良好，与积极监测相比，在预防或延缓高风险SMM患者进展为活动性MM方面显示出统计显著且具有临床意义的益处。 公开资料显示，SMM是多发性骨髓瘤 ...
10月21日，$强生(JNJ)$ 宣布
10月21日，$强生(JNJ)$宣布，旗下创新治疗药物泽倍珂（尼拉帕利+阿比特龙片）正式获得国家药品监督管理局批准。用于治疗携带胚系和/或体系 BRCA 基因突变的转移性去势抵抗性前列腺癌成人患者（mCRPC）。11月5日，$辉瑞(PFE)$的甲苯磺酸他拉唑帕利胶囊（talazoparib）的上市申请已获得批准。 此外，还有一款PARP抑制剂塞纳帕利（senaparib，英派药业/华东医药）已申报 ...
news.stocktradersdaily2 天
How to Take Advantage of moves in (JNJ)
GET MORE AI-GENERATED SIGNALS: November 09, 2024, 09:42 am ET, BY Chris- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...
强生(JNJ.US)单抗疗法公布3期积极数据 实现显著的临床缓解和内镜应答
智通财经APP获悉，日前，强生(JNJ.US)公布其白细胞介素-23（IL-23）靶向抗体Tremfya（guselkumab）在GRAVITI临床3期研究的积极结果。研究结果显示，在48周时，接受Tremfya作为诱导和维持治疗的中至重度活动性克罗 ...
Protagonist Therapeutics: Buy Rating Backed by Promising Phase 3 Catalysts and Strategic ...
Protagonist Therapeutics (PTGX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
bovnews5 天
JNJ Stock Fluctuations: The Real Story
On Tuesday, Johnson & Johnson (JNJ) stock saw a modest uptick, ending the day at $158.35 which represents a slight increase of $0.11 or 0.07% from the prior close of $158.24. The stock opened at $157.
Daily1 天
JnJ seeks approval from USFDA, EMA for DARZALEX FASPRO as subcutaneous monotherapy for high ...
Raritan: Johnson & Johnson has announced the submission of regulatory applications to the U.S. Food and Drug Administration ...
强生公司寻求FDA和EMA批准骨髓瘤治疗新适应症
新泽西州拉里坦 - 强生公司（NYSE:JNJ）已向美国食品和药物管理局（FDA）和欧洲药品管理局（EMA）提交申请，为DARZALEX FASPRO®（达雷妥尤单抗和透明质酸酶-fihj）增加一项新的适应症，用于治疗高风险潜伏性多发性骨髓瘤，这是活动性多发性骨髓瘤的前兆。如果获得批准，DARZALEX FASPRO®将成为首个被批准用于这类患者群体的治疗方案，可在全面疾病发作前使用。 这些申请基 ...
强生11月7日成交额为11.79亿美元 在当日美股中排第66名
2024年11月7日，制药公司强生（JNJ）成交额为11.79亿美元，在当日美股中排第66名，成交额较昨日减少16.48%，当日成交量为751.03万。 强生（JNJ）于2024年11月7日跌0.73%，报156.73美元，该股过去5个交易日跌1.96%，整个11月跌1.96%，年初至今跌0.01%，过去52周涨4.24%。 *如果公司上市时间少于52周，则52周涨跌幅为上市至今涨跌幅（同样适用于 ...